Misplaced Pages

Maximum androgen blockade

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Maximal androgen blockade)

Maximum or maximal androgen blockade (MAB) or complete or combined androgen blockade (CAB) is a medical treatment involving the combination of both androgen receptor (AR) antagonism and inhibition or suppression of androgen production to attain maximal effectiveness in androgen deprivation therapy (ADT). An example of MAB is the combination of bicalutamide, an AR antagonist, with a gonadotropin-releasing hormone (GnRH) analogue such as leuprorelin or cetrorelix. MAB was developed for and is employed in the treatment of prostate cancer.

Triple androgen blockade (TrAB) is a method of ADT in which a 5α-reductase inhibitor such as finasteride or dutasteride is added to CAB.

MAB has been found to produce higher rates of gynecomastia (7 to 28%) than orchiectomy and GnRH analogues alone (1 to 16%), but lower rates than nonsteroidal antiandrogen monotherapy such as with bicalutamide (30 to 85%).

References

  1. ^ "Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials". The Lancet. 355 (9214): 1491–1498. 2000. doi:10.1016/S0140-6736(00)02163-2. ISSN 0140-6736. S2CID 25366526.
  2. Hellerstedt, Beth A; Pienta, Kenneth J (2003). "The truth is out there: an overall perspective on androgen deprivation". Urologic Oncology: Seminars and Original Investigations. 21 (4): 272–281. doi:10.1016/S1078-1439(03)00046-2. ISSN 1078-1439. PMID 12954498.
  3. Leibowitz RL, Tucker SJ (2001). "Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients". The Oncologist. 6 (2): 177–82. doi:10.1634/theoncologist.6-2-177. PMID 11306729.
  4. Di Lorenzo G, Autorino R, Perdonà S, De Placido S (December 2005). "Management of gynaecomastia in patients with prostate cancer: a systematic review". Lancet Oncol. 6 (12): 972–9. doi:10.1016/S1470-2045(05)70464-2. PMID 16321765.
Androgens and antiandrogens
Androgens
(incl. AASTooltip anabolic–androgenic steroid)
ARTooltip Androgen receptor agonists
Progonadotropins
Antiandrogens
ARTooltip Androgen receptor antagonists
Steroidogenesis
inhibitors
5α-Reductase
Others
Antigonadotropins
Others
See also
Androgen receptor modulators
Estrogens and antiestrogens
Progestogens and antiprogestogens
List of androgens/anabolic steroids
Androgen receptor modulators
ARTooltip Androgen receptor
Agonists
SARMsTooltip Selective androgen receptor modulator
Antagonists
GPRC6A
Agonists
See also
Receptor/signaling modulators
Androgens and antiandrogens
Estrogen receptor modulators
Progesterone receptor modulators
List of androgens and anabolic steroids


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it.

Categories: